



Published in final edited form as:

Nat Commun. ; 3: 782. doi:10.1038/ncomms1779.

The structure of the FANCM-MHF complex reveals physical features for functional assembly

Yuyong Tao^{1,2}, Changjiang Jin^{1,2,3}, Xu Li^{1,2}, Shali Qi^{1,2}, Lingluo Chu^{1,2,3}, Liwen Niu^{1,2}, Xuebiao Yao^{1,2,3,*}, and Maikun Teng^{1,2,*}

¹Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China

²Key Laboratory of Structural Biology, Chinese Academy of Sciences, Hefei, Anhui 230026, China

³Anhui-MSM Joint Research Group for Cellular Dynamics, Hefei, Anhui 230027, China

Abstract

Fanconi anemia (FA) is a rare genetic disease characterized by chromosomal instability and cancer susceptibility. The Fanconi anemia complementation group protein M (FANCM) forms an evolutionarily conserved DNA-processing complex with MHF1/MHF2 (histone-fold-containing proteins), which is essential for DNA repair in response to genotoxic stress. Here we present the crystal structures of the MHF1-MHF2 complex alone and bound to a fragment of FANCM (FANCM⁶⁶¹⁻⁸⁰⁰, designated FANCM-F). The structures show that MHF1 and MHF2 form a compact tetramer to which FANCM-F binds through a “dual-V” shaped structure. FANCM-F and (MHF1-MHF2)₂ cooperate to constitute a new DNA-binding site that is coupled to the canonical L1L2 region. Perturbation of the MHF-FANCM-F structural plasticity changes the localization of FANCM in vivo. The MHF-FANCM interaction and its subcellular localization are altered by a disease-associated mutant of FANCM. These findings reveal the molecular basis of MHF-FANCM recognition and provide mechanistic insights into the pathway leading to FA.

Introduction

The effective repair of DNA damage, caused by exogenous agents or arising during DNA replication, confers protection from malignant transformation. Several genetic disorders that perturb the repair of DNA damage result in an elevated predisposition to cancer. One such disorder is a rare, multigenic syndrome known as Fanconi anemia (FA), which is characterized by developmental defects, bone marrow failure, and chromosomal instability¹⁻³. Mutations in any of these 15 known *FANCM* genes can result in dysfunctions in DNA damage repair, leading to FA²⁻⁷. FA cells are susceptible to agents that induce DNA interstrand crosslinks (ICLs), which block the progression of the replication fork. In

Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Corresponding author: xyao@msm.edu; or mkteng@ustc.edu.cn.

Accession codes: Atomic coordinates and structure factors for the MHF1-MHF2 and MHF-FANCM complex have been deposited in the Protein Data Bank under the accession codes 4DRA and 4DRB, respectively.

response to DNA damage, FANCL in the FA core complex, composed of eight FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and -M)³, monoubiquitinates the FANCD2-FANCI complex^{8,9}. Once ubiquitinated, this complex recruits the downstream FA proteins, and the pathway for homologous recombination-dependent DNA repair is activated¹⁰. The recently identified FA-related protein, FAN1, may act as a direct effector, processing the ICL with its exonuclease activity upon binding to ubiquitinated FANCD2-FANCI through its ubiquitin-binding zinc-finger (UBZ) domain¹¹⁻¹⁴.

As a component of the FA core complex, FANCM contains an evolutionarily conserved helicase domain bearing ATP-dependent DNA translocase activity¹⁵⁻¹⁷. In addition to its interactions with other FA proteins¹⁸, FANCM possesses an activity for binding to branch-structured DNA¹⁶, which is required for efficient monoubiquitination of the FANCD2-FANCI heterodimer¹⁹. Recently, two histone-fold-containing proteins, MHF1 and MHF2, were identified as FANCM-associated factors^{20,21}. The MHF1-MHF2 complex (abbreviated MHF) binds double-strand DNA (dsDNA)^{20,21}, stimulates the DNA-binding activity of FANCM, and contributes to FANCM targeting to chromatin²¹. A stable association with FANCM and DNA-binding activity are required for MHF to function in activation of the FA pathway^{20, 21}. Moreover, like FANCM, MHF is conserved, from yeast to human^{20,21}, suggesting the functional importance of the MHF-FANCM complex in eukaryotes. It is unclear, however, how FANCM physically interacts with MHF and whether the MHF-FANCM interaction is perturbed in the disease-associated mutant, FANCM^{S724X}. In addition, MHF1 and MHF2 are constitutive, centromere-associated network (CCAN) proteins of CENP-S and CENP-X, which are implicated in assembly of the outer kinetochore^{22, 23}. However, it has remained to be determined whether CENP-S/X assembles into functional nucleosomes at the centromere and how those CENP-S/X-containing nucleosomes relate to the classical CENP-A-containing nucleosomes.

Here we report the crystal structures of the MHF1-MHF2 complex alone and bound to FANCM⁶⁶¹⁻⁸⁰⁰ (FANCM-F). The structures show that MHF1 and MHF2 form a (MHF1-MHF2)₂ tetramer (MHF) and that FANCM-F binds to it through a “dual-V” shaped structure. The (MHF1-MHF2)₂ tetramer cooperates with FANCM-F in DNA-binding through constructing an additional site on the complex. Perturbation of the MHF-FANCM-F interaction by FANCM^{S724X} changes the FANCM localization in vivo, which suggests a potential mechanism underlying the pathogenesis of FA.

Results

Overall structure of MHF1-MHF2 complex

To gain further insights into FA, we carried out structural studies on the MHF-FANCM complex. Since full-length MHF1 in complex with MHF2 failed to yield crystals, truncated MHF1 with the C-terminal 31 residues deleted was used for crystal growth and structure determination (**Methods**) (Table 1). The structure shows that four MHF1-MHF2 heterodimers occupy the asymmetric unit (Fig. 1a, b) and they have an essentially identical structure, as revealed by structural superposition (0.69 Å RMSD). In addition to the three central α helices for MHF1 and MHF2, an additional C-terminal α C helix is included in MHF1 (Fig. 1a-d). The MHF1-MHF2 heterodimer is mediated by the histone-fold in a head-

to-tail fashion, commonly found in histone-like proteins²⁴⁻²⁶. Numerous hydrophobic and polar contacts occur at the dimer interface and result in a buried surface area of about 2245 Å² (Fig. 1e), which is consistent with their stable association during the purification process. MHF1 uses its C-terminal parts of α2 and α3 to assemble into a (MHF1-MHF2)₂ tetramer, constructing a four-helix bundle with a pseudodyad passing across the interface (Fig. 1b and Supplementary Fig. S1), as occurs for (H3-H4)₂ and (CENP-A-H4)₂^{27,28}.

Structural features of MHF1-MHF2 complex

Although MHF1/MHF2 belongs to H2A/H2B family due to the existence of MHF1 αC helix, MHF1 preserves the partial feature of H3/H4, evident by the presence of an intra-chain arginine-aspartate bidentate pair observed in H3/H4 and NC-Y^{24,27}. MHF1 residues Arg73 and Asp81, conserved across species (Fig. 1c), interact electrostatically with each other, whereas MHF2 Arg64 is positioned too close to Asp66 to form that kind of bidentate (Fig. 2a-b, c). MHF1-MHF2 and H2A-H2B heterodimers superimpose with a 2.46 Å RMSD over Ca atoms located in histone-fold regions. A corresponding MHF1-MHF2 and H3-H4 superposition has a 1.88 Å RMSD. Significant structural differences between MHF1/MHF2 and H2A/H2B reside in the N-terminus of MHF1 and C-terminus of MHF2. MHF1 lacks the N-terminal extension as that of H2B, but processes a longer α1 helix (Fig. 2d); MHF2 does not contain additional C-terminal helix and tail (Fig. 2a). Further, the MHF2 α3 helix adopts a different conformation and it is more bent toward α2 (Fig. 2e). There are two reasons for the helix kink. First, the insertion of Pro75 into the primary sequence destroys the continuation of the α3 helix (Fig. 2e). Second, the hydrophobic core, comprised of MHF1 Leu92, MHF2 Val44, Phe45, Leu77, Phe81, as well as intra-chain electrostatic contacts between MHF2 Arg52 and Asp80, restrains the local conformation (Fig. 2e). Notably, the residues participating in above interactions are highly conserved across species (Fig. 1c-f).

Structural superimposition of one MHF1-MHF2 heterodimer to that of (H3-H4)₂ reveals that the (MHF1-MHF2)₂ tetramer adopts a highly compact structure (Fig. 2f). First, the bent of MHF1 α2 helix toward MHF2 induced by the hydrophobic interactions positioned in the N-terminal part of the MHF1 α2 helix gives a close proximity (Fig. 2f). Second, the rotation between the dimer pairs of (MHF1-MHF2)₂ relative to that of (H3-H4)₂ further tightens the tetramer (Fig. 2f). A series of hydrophobic and polar contacts within the four-helix bundle interface maintains the rotation divergence. In addition to the hydrogen bonds between His71 and Asp81', which is conserved in (H3-H4)₂, the hydrophobic interaction mediated by the aliphatic side of Met67 and aromatic ring of Phe68 stabilizes the tetramer (Fig. 1c and 2g). Notably, Arg87' not only participates in the hydrophobic interaction through aliphatic portion of side chain, but, together with Arg88', forms ion pairs with Asp64 (Fig. 2c). These ion pairs, positioned further away from the top interactions, thus contribute to a specialized α2-α2' conformation. In sum, our structural observations reveal that MHF1 and MHF2 form a compact tetramer.

FANCM binds to the (MHF1-MHF2)₂ tetramer

FANCM was previously found to associate with MHF1-MHF2 through the region consisting of residues 661-800²¹. We co-crystallized the FANCM fragment (FANCM⁶⁶¹⁻⁸⁰⁰, designated FANCM-F) with MHF1-MHF2 and determined the structure of the complex

(Table 1). The structure shows that one FANCM-F molecule binds to a (MHF1-MHF2)₂ tetramer and that FANCM-F exhibits an extended conformation (Fig. 3a, b). The binding of FANCM-F to a pseudodyad-related (MHF1-MHF2)₂ tetramer results in a pseudo-two-fold symmetric shape of FANCM-F, like two “V”s connected by a linker coil passing through the interspace formed by the two α3 helices of MHF2/MHF2'. Without association with MHF, FANCM-F appears to be disordered in solution, as the residues that do not participate in the interaction with MHF, including the N- and C-terminal FANCM-F and residues 730-750, either have no electron density or are highly flexible (Fig. 3c,d). The ordered portion of FANCM-F, folding into three α helices and irregular coil with elements of two small β strands and two ₃₁₀ helices, remains in almost continuous contact with (MHF1-MHF2)₂ through wrapping around the MHF1 α1, α2 and MHF2 α2, α3 helices (Fig. 3a, b).

The MHF1-FANCM-F interaction is characterized by the pseudo-symmetry with each “V” segment and the associated MHF1-MHF2 dimer as a subregion. FANCM-F αA helix spans MHF1 α1 and makes interactions by forming a complementary hydrophobic interface consisting of FANCM-F residues Leu680, Glu684, Leu687, Trp688, Tyr692 and MHF1 residues Ala21, Ala22, His24, Tyr25, Cys29 (Fig. 3e). Accordingly, FANCM-F αC together with the following ₃₁₀ helix and 3-residue linker surrounds the same region of MHF1' on the other side, which involves FANCM-F residues Val781, Tyr784, Leu785, Met787, Val790 (Fig. 3f). MHF1' residue Arg18' forms three hydrogen bonds with Gln786 and Asp789 of FANCM-F through side chain (Fig. 3f). Following αA, β1 is kept in position through hydrophobic interactions between FANCM-F residues Leu694, Ile703, Leu705, Leu731 and MHF1 residues Gln45, Ala48, Ala49, Glu52, Leu53 and Arg56, located within the N-terminus of α2 (Fig. 3e). Notably, the FANCM-F residues 727-730, making five pairs of hydrogen bonds with β1, fold into the β2 strand, which is used to rotate the polypeptide for the arrival at the other side of the tetramer (Fig. 3g). The FANCM-F αB helix, equivalent to the β1 strand, packs against the MHF1' α2' helix in an anti-parallel manner, with its hydrophobic side facing α2' (Fig. 3f).

FANCM-F αB helix and the linker coil are the main elements constructing the MHF2-FANCM-F interface, which buries a total surface area of about 2161 Å². Besides the contacts with MHF1, FANCM-F αB also packs against the two α3 helices of MHF2/MHF2', generating hydrophobic interactions as well as three hydrogen bonds together with the flanking Arg769 (Fig. 3h). The coil immediately N-terminal to the FANCM-F αB, sticks to the surface created by MHF2 α2' and α3', thus preventing the MHF2 hydrophobic coil from solvent access (Fig. 3i). The N-terminal counterpart coil lacks the broad interface, but an aromatic residue Phe710 instead of the equivalent Val749, is used to interact with the MHF2 hydrophobic core (Fig. 3i, j). The loop and following ₃₁₀ helix passing across the interspace of the two α3 helices of MHF2/MHF2' further occlude the MHF2 hydrophobic core at the bottom through a series of interactions, among which FANCM-F Trp736 and Trp739 embedding the aliphatic portion of MHF2 Lys72 side chain stands out (Fig. 3k). The extensive buried surface area of about 4328 Å² between MHF and FANCM-F explains their stable association in vivo^{20, 21}.

The (MHF1-MHF2)₂ tetramer from the MHF-FANCM-F bears a similar structure as that of MHF complex alone (0.87 Å RMSD). The main differences between the two structures

reside in the N- and C-termini of MHF1/MHF1'. For MHF1 in MHF-FANCM-F, α C not only becomes longer, but moves about 2 Å toward FANCM-F (Fig. 3l). For MHF1', α 1' becomes two turns longer with the additional traced residues (Fig. 3l). Both the C-terminal parts of α 2 and α 2' in MHF2/MHF2' are slightly bent away from the position in the MHF complex alone (Fig. 3l). In summary, (MHF1-MHF2)₂ tetramer retains the rigid structure and interface upon binding with FANCM-F.

Centromere localization of the (MHF1-MHF2)₂ tetramer

As observed above, the finding of compact (MHF1-MHF2)₂ tetramer being retained in MHF-FANCM-F complex prompted us to speculate that the structural rigidity of (MHF1-MHF2)₂ is required for its *in vivo* function. To test the hypothesis, we generated two MHF1 mutants that were designed to disrupt the four-helix bundle: MHF1^{D64A/F68A} and MHF1^{H71A/D81A} (Supplementary Fig. S1). Consistent with the structural observation, immunoprecipitation results showed that both Flag-tagged MHF1 mutants were incapable of associating with GFP-tagged MHF1 (Fig. 4a). Although wild-type MHF1 localized to the centromere marked by ACA (anti-centromere antibody, Fig. 4b), the MHF1^{H71A/D81A} mutant failed to localize properly, suggesting that functional assembly of MHF1 dimer is essential for proper targeting and/or stable localization (Fig. 4b). In fact, the previous study has shown that MHF1^{R87A/R88A}, where mutations again are involved in the four-helix bundle interface, exhibits functional defects in activation of the FA pathway²¹. To destabilize the fold of the tetramer, we destroyed the MHF2 hydrophobic core by mutating the last two residues (Asp80/Phe81) of MHF2 into alanines (MHF2^{D80A/F81A}) (Supplementary Fig. S1). As anticipated, the mutant failed to localize to the centromere (Fig. 4c). Although MHF2 residues Asp80 and Phe81 do not participate in the direct physical contact with MHF1, the association between MHF1 and MHF2 was perturbed by their mutations (Fig. 4d). Moreover, MHF1 residues Asp64, Phe68, His71, Asp81, Arg87 and Arg88 that are not in direct contact with MHF2 are important for MHF2 binding as well as for FANCM association *in vivo*²¹. These data suggest that assembly of the functional MHF-FANCM complex depends on the structural integrity of each unit and that the integrity of (MHF1-MHF2)₂ is essential for its distribution and function in cell culture.

L1L2 and the C-terminal MHF1 is necessary for MHF DNA-binding

The DNA-binding activity of the MHF complex is necessary for its functions in cell culture, including FANCD2 monoubiquitination and suppression of sister-chromatid exchanges (SCEs)^{20,21}. As occurs for (H3-H4)₂, the calculated electrostatic surface potential of (MHF1-MHF2)₂ tetramer shows a positive charge on the convex side (Fig. 5a, b), which is probably involved in DNA-binding. By superimposing the MHF1-MHF2 dimer onto H2A-H2B from nucleosomes or NC2 α -NC2 β ^{25, 26}, we concluded that the bound DNA fragment on the (MHF1-MHF2)₂ tetramer would follow a similar trajectory as that complexed with H2A-H2B or NC2 α -NC2 β (Fig. 3c, d), and L1L2 (The region composed by MHF1 L2 loop and MHF2 L1 loop, Fig. 1) is the DNA-binding site of (MHF1-MHF2)₂, which is consistent with the amino acid conservation in L1L2 (Fig. 1c, d).

Consistent with the structural analyses, MHF1^{K73A/R74A} exhibits diminished DNA-binding activity²¹ (Fig. 5e). Similarly, as shown in Fig. 5e, 5f and 5g, MHF2^{K27A/K29A} exhibits a

reduced binding affinity to dsDNA, judged by a significant increase in the dissociation constant (K_d). Several residues in $\alpha 1\alpha 1$ of H2A-H2B from nucleosome or NC2 α -NC2 β are in direct contact with DNA^{26,27}, thus contributing to the stability of the DNA-protein complex. However, the basic amino acids in the $\alpha 1\alpha 1$ of MHF seem to be dispensable in DNA-binding, as the combination mutant of MHF1^{R12A/R18A} and MHF2^{R11A/K12A} exhibits a slightly reduced DNA-binding affinity relative to the wild-type protein (Fig. 5e). Although the double mutant associates with dsDNA, we could not rule out the possibility that the MHF basic residues in $\alpha 1\alpha 1$ make contacts with DNA when the substrate is bound on the MHF. The likely reason that MHF1 R12A/R18A and MHF2 R11A/K12A mutations have little influence on the DNA-binding activity is that the L1L2 site alone is strong enough to support DNA-binding.

The C-terminus of MHF1 is indispensable for the DNA-binding activity of the MHF complex²⁰. We confirmed the result by using the truncated complex for structure determination (Fig. 3h). Consistent with the previous observation, a 7-residue extension at the C-terminus of the above truncation restored the DNA-binding activity, although with slightly lower affinity compared to the wild-type complex (Fig. 3h). MHF1^{R110A/K111A} in complex with MHF2 also exhibited a decreased DNA-binding affinity (Fig. 3g). Although the C-terminus of MHF1 is predicted to be flexible and is not included in our structure, it may become ordered when associating with DNA substrate, as speculated from alignment of MHF1-MHF2 with NC2 α -NC2 β (Fig. 3d). We conclude that both the L1L2 site and C-terminal MHF1 are the molecular determinants for MHF1-MHF2 complex binding to DNA.

MHF cooperates with FANCM-F in promoting DNA-binding

Previous studies have revealed that FANCM stimulates the DNA-binding activity of MHF and vice versa²¹. As mentioned above, no structural allostereism is observed for the (MHF1-MHF2)₂ tetramer upon FANCM-F binding; however, its electrostatic surface potential is changed. As shown in Fig. 6a and 6b, the $\alpha 1\alpha 1$ area of MHF-FANCM-F becomes more electropositive and broader than that of MHF alone because of the addition of FANCM-F N-terminal residues Lys675, Lys676, Lys686, Arg690, and Arg693, while the positive charge of the $\alpha 1'\alpha 1'$ site is neutralized by the Glu and Asp residues present at the C-terminus of FANCM-F. When we analyzed the DNA-binding profile of MHF-FANCM-F by fluorescence polarization assay (FPA), the two-site-binding mode was needed to fit the experimental data, which is different from the one-site-binding mode of MHF complex alone (Fig. 5f and 6c). Surprisingly, the calculated K_d^1 for MHF-FANCM-F is about 10-fold lower than that of MHF (Fig. 5f and 6c). This is reminiscent of the DNA-binding synergy between MHF and FANCM. Thus, we reasoned that MHF $\alpha 1\alpha 1$ and FANCM-F N-terminus cooperate to create a new DNA-binding site (designated as the $\alpha 1\alpha 1$ site) upon formation of a MHF-FANCM-F complex, in addition to the canonical L1L2 site. If this were the case, MHF-FANCM-F complex would still possess a DNA-binding property, even if MHF were in mutant form: MHF1^{K73A/R74A}/MHF2 or MHF1/MHF2^{K27A/K29A}. Indeed, our electrophoretic mobility shift assay (EMSA) results showed that MHF1^{K73A/R74A}/MHF2/FANCM-F interacts with DNA and that MHF1/MHF2^{K27A/K29A}/FANCM-F acts in a similar manner (Fig. 6d). We then determined if mutations in the N-terminus of FANCM-F would disrupt the $\alpha 1\alpha 1$ site by constructing two FANCM-F mutants: FANCM-

FK675A/K676A and FANCM-F^{FK686A/R690A/R693A}. MHF1^{K73A/R74A}/MHF2/FANCM-F^{FK675A/K676A} lost the DNA-binding activity, and MHF1^{K73A/R74A}/MHF2/FANCM-F^{FK686A/R690A/R693A} showed defects in DNA-binding (Fig. 6e). Moreover, when FANCM-F^{FK686A/R690A/R693A} was complexed with MHF bearing MHF1 R12A/R18A/K73A/R74A mutations, it completely lost DNA-binding activity (Fig. 6e). Similarly, when FANCM-F^{FK675A/K676A} was complexed with MHF1^{K73A/R74A} and MHF2^{R11A/K12A}, any unspecific background was eliminated (Fig. 6e).

We next determined the function of the MHF1 C-terminus in the DNA-binding activity of MHF1/MHF2/FANCM-F. MHF1¹⁻¹⁰⁷/MHF2/FANCM-F still showed no DNA-binding activity (data not shown); MHF1¹⁻¹¹⁴/MHF2/FANCM-F interacted with DNA, but it exhibited one-site-binding mode (Fig. 6f), implicating the disruption of the $\alpha 1\alpha 1$ site when the C-terminal MHF1 is removed. Based on the above results, we propose that the MHF-FANCM-F complex possesses two DNA-binding sites (Fig. 6g) and that they are not independent, but coupled by the C-terminus of MHF1 and bind to DNA synergistically.

The (MHF1-MHF2)₂ tetramer localizes FANCM to centromeres

To determine the effect of MHF1 on FANCM localization, HeLa cells were transiently transfected to express GFP-FANCM and siRNA to suppress the endogenous MHF1. As shown in Fig. 7a, GFP-FANCM locates to the centromeres in the scramble-transfected cells based on the superimposition of ACA staining with GFP-FANCM. A survey of 200 cells positively transfected revealed that majority of GFP-FANCM-expressing cells (>95%) exhibits a typical co-localization profile shown in Fig. 7a. However, the centromere localization of GFP-FANCM is diminished when MHF1 is suppressed. Less than 5% cells containing centromeric GFP-FANCM signal when MHF1 is knock-down (n=200), suggesting that MHF1-MHF2 structural integrity is essential for localization of FANCM.

FANCM and MHF constitutively associate with each other in vivo²¹. To determine if the (MHF1-MHF2)₂ tetramer is essential for a stable FANCM association with chromatin, HeLa cells were transiently transfected to express FLAG-MHF1 and FLAG-MHF1^{H71A/D81A} together with Myc-tagged FANCM, followed by subcellular fractionation to separate the chromatin fraction (P) from cytosolic fractions (S2 and S3) using differential centrifugation²⁹. Consistent with the previously published results²⁹, Myc-FANCM was exclusively detected in the chromatin fraction (P) of wild-type MHF1-expressing cells (Fig. 7b, **lane 5**). FANCM distributed across the S2, S3, and P fractions of both FLAG-MHF1-expressing cells and FLAG-MHF1^{H71A/D81A}-expressing cells, as previously described. However, mutant MHF1^{H71A/D81A} was found only in the S2 fraction, consistent with our early immunofluorescence study (Fig. 4b), and suggesting that perturbation of the (MHF1-MHF2)₂ tetramer abolishes the association of MHF1 with chromatin. Most of myc-FANCM becomes relocated in mutant MHF1-expressing cells (e.g., FLAG-MHF1^{H71A/D81A}-expressing cells), supporting the notion that FANCM is localized to chromatin when functional integrity of the MHF complex is present. A minor amount of myc-FANCM remains associated with chromatin fraction (Fig. 7b; **lane 6**), which represents the myc-FANCM bound to the endogenous MHF complex.

Localization of FANCM to chromatin

Given the dependence of FANCM on the MHF complex in chromatin localization, we determined if the disease-associated mutant FANCM^{S724X} retains the capacity to bind the MHF complex and co-distributes with MHF to centromeres¹⁵. Since Ser724 is situated in the top center of the “dual-V” shaped FANCM-F, deletion mutant near Ser724 would perturb the interaction of FANCM-F with (MHF1-MHF2)₂ (Fig. 7c). To this end, we performed a pull-down assay using GST-FANCM-F fusion protein as an affinity matrix to isolate recombinant MHF protein from bacteria. As shown in Fig. 7d, GST-FANCM-F binds tightly to MHF (**lane 1**). In contrast, little MHF protein binds to GST-FANCM⁶⁶¹⁻⁷³⁰ (**lane 2**).

To establish that FANCM^{S724X} perturbs its localization with MHF, we performed immunofluorescence experiments in which HeLa cells were transiently transfected to co-express Myc-MHF1 with GFP-FANCM or GFP-FANCM¹⁻⁷²³. As predicted, GFP-FANCM colocalized with Myc-MHF1 to the centromere marked by ACA (Fig. 7e). However, GFP-FANCM¹⁻⁷²³ failed to localize with Myc-MHF1 to the centromere labeled with ACA (Fig. 7e), which is consistent with the pull-down assay (Fig. 7d). These data reveal that the “dual-V” structure of FANCM is indispensable for its association with MHF and disruption of the “dual-V” structure by the disease-associated mutation (S724X) causes failure in targeting of FANCM¹⁻⁷²³ to chromatin, which may partially explain the pathogenesis of such mutations in FA patients.

Discussion

In this investigation, we determined the crystal structures of the MHF1-MHF2 and MHF-FANCM-F complexes. By adopting the histone-fold motif, MHF1 and MHF2 are arranged into a tetramer, similar to the (H3-H4)₂ within histone octamers. Given the function of the MHF (CENP-S/X) complex in the assembly of kinetochores^{22, 23}, the information from our structure-functional analyses shows that plasticity of the MHF-FANCM complex is involved in maintaining genomic stability during cell division.

FANCM binds to the (MHF1-MHF2)₂ tetramer, with each dimer as a subregion. The extensive interface between MHF and FANCM guards the stability of the assembled MHF-FANCM complex; thus, they translocate together to the damaged DNA site for subsequent loading and/or assembly of FA core complex⁴. The FANCM mutation S724X in FA individuals¹⁵ would lead to truncated products of FANCM¹⁻⁷²³. Our structural observations indicate that FANCM-F bears the “dual-V” shaped configuration for physical contact with MHF. FANCM⁶⁶¹⁻⁷³⁰ is unable to bind to MHF, mainly due to the fact that truncation disrupts the “dual-V” shaped configuration of FANCM-F and the interface between MHF and FANCM-F. In addition, the FANCM¹⁻⁷²³ deletion mutant failed to localize with MHF1 in the centromere of culture cells, suggesting that “dual-V”-shaped FANCM forms a stable complex with the (MHF1-MHF2)₂ tetramer, which is essential for FANCM binding to chromatin. Our results provide insight into how a mutation in FANCM^{S724X} causes mis-localization of FANCM to the chromatin. The results contribute to understanding of the etiology of Fanconi anemia. Given the importance of MHF in assembly of a stable MHF-FANCM to centromeres (Fig. 7a), the perturbation of stable MHF-FANCM complex

formation by FANCM^{S724X} may also impair the assembly of FA core complex at chromatin. Our future studies will aim to determine how the mutant FANCM alters the FA core complex activity and establish the contribution of disease-associated FANCM mutant to the pathogenesis of Fanconi anemia.

How the MHF-FANCM complex recognizes the DNA damage interstrand cross-links (ICLs) and is rapidly recruited to the damage site from the centromere site in chromatin remains elusive. Our structural observations demonstrate that MHF and FANCM, by forming a stable complex, ensure the physical association with chromatin *in vivo*. The mechanism for regulation of FANCM ATPase activity and the mechanism underlying translocation of the MHF-FANCM complex along the chromatin and recognition of ICLs will require further studies at single molecule analyses in real-time preferably with a small molecule inhibitor. CENP-A is rapidly recruited to double-strand breaks in DNA, along with several centromeric components, such as CENP-U^{30,31}. The centromere-targeting domain of CENP-A is necessary and sufficient for recruitment to double-strand breaks. Given the structural similarities in CENP-A and MHF and the kinetochore localization of MHF^{23,28}, it would be of interest to determine if MHF and CENP-A and other histones form nucleosomes *in vitro* and *in vivo* at the double-strand breaks. It would be important to know if the MHF nucleosomes are different from the classic CENP-A-containing nucleosomes and how they interact at the double-strand breaks. Finally, it is worth noting that MHF1 and MHF2 (under the name of CENP-S and CENP-X) are constitutive components of centromere^{23,28}. Future studies using biophotonic tools such as FRET-based biosensors³² should illustrate the central questions such as the spatiotemporal dynamics of MHF1-MHF2 complex relative to CENP-A nucleosome during cell division cycle and the functional specificity of the aforementioned complexes in DNA damage repair and kinetochore plasticity. Molecular delineation of those questions will shed light into a better understanding of the epigenetic mechanisms underlying centromere plasticity and genomic stability in mitosis³³.

Taken together, our structural and functional analyses of the MHF-FANCM-F complex have provided insights into the specificity of FANCM recognition by the (MHF1-MHF2)₂ tetramer and have advanced our understanding of the MHF-FANCM orchestration in MHF-chromatin binding. The results of this study should facilitate analyses of the molecular mechanism of replication fork surveillance and perhaps centromeric chromatin assembly.

Methods

Cell culture

HeLa and HEK293T cells were grown at 37 °C in DMEM (Invitrogen) containing 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin with 8% CO₂ in a humidified incubator.

Recombinant protein preparation

All the DNA fragments of human MHF1, MHF2 and FANCM⁶⁶¹⁻⁸⁰⁰ (FANCM-F) were amplified from a human brain cDNA library by PCRs. The MHF1 DNA fragment was

cloned into a modified pET-28a (+) vector without the thrombin cleavage site using the NdeI/XhoI restriction site. The DNA fragments of MHF2 and FANCM-F were inserted into another modified pET-28a (+) with a MBP-TEV cleavage site tag in the N-terminal recombinant proteins, respectively. All the mutants were generated using two-step PCR and subcloned, overexpressed, and purified in the same way as that of wild-type protein. Overexpression of all recombinant proteins was induced in *E. coli* Rosetta (DE3) (Novagen) by 0.5 mM isopropyl-b-D-thiogalactoside (IPTG) when the cell density reached $OD_{600\text{ nm}}=0.6-0.8$. After a growth for about 20h at 16°C, the cells were collected and lysed. The recombinant proteins were purified using Ni^{2+} -nitrilotriacetate affinity resin (Ni-NTA, Qiagen) in 20 mM Tris-HCl, pH 8.0, and 200 mM NaCl. Then the MBP tag in the target protein was removed by TEV digestion at 4°C overnight. The proteins were further purified using HiTrap Q FF (5 ml) and HiLoad 16/60 Superdex 200 (GE Healthcare). The final proteins in buffer containing 20mM Tris-HCl, pH 7.5 and 50mM NaCl were concentrated to 40-60 mg/ml for crystallization trials.

To prepare the SeMet-derivative protein, MHF complex was expressed in *E. coli* strain B834 (Novagen) using M9 medium supplemented with SeMet and six amino acids, including leucine, isoleucine, valine, phenylalanine, lysine, and threonine. The SeMet-derivative MHF protein was then copurified with native FANCM-F protein by a procedure similar to that described above.

Crystallization

Full-length MHF1 (1-138 aa) and the three different truncations containing residues 1-107 aa, 1-114 aa and 1-122 aa in complex with MHF2 were all subjected to crystal screens, respectively. Both MHF1¹⁻¹⁰⁷/MHF2 and MHF1¹⁻¹¹⁴/MHF2 complex yielded crystals, but only the former one, which was grown in 0.1M HEPES-NaOH, pH 6.8, diffracted well enough to allow data collection. The above three versions of truncated MHF in complex with FANCM-F were again used for crystal screen, respectively. The crystal of MHF1¹⁻¹¹⁴/MHF2/FANCM-F diffracted best and then such truncation was used for subsequent SeMet-derivative protein preparation and crystal growth. Both the native and SeMet-derivative MHF-FANCM-F crystals appeared in 0.1M Tris-HCl, pH 8.5, 0.2M (NH₄)₂SO₄ and 25% PEG3350 and grew to the maximum size in about 72h. For MHF-FANCM-F, both native and heavy atom-derived crystals were directly flash frozen in a cold nitrogen stream at 100 K. For MHF, the crystals were co-cryoprotected in buffer containing 0.1M HEPES-NaOH, pH 6.8 and 30% glycerol. All the crystal screen attempts were carried out using hanging drop vapor diffusion method at 285 K.

Data collection and structure determination

All data were collected at beamline BL17U of Shanghai Synchrotron Radiation Facility (SSRF) and processed with the HKL2000 package³⁴ and programs in the CCP4 suite³⁵. For SeMet-derivative MHF-FANCM-F crystal, data were collected at the wavelength near the selenium absorption edge. The single wavelength anomalous scattering data of MHF-FANCM-F collected from a single SeMet-derivative crystal was enough to calculate the initial phases. The phases were calculated by PHENIX.AutoSol³⁶ and a FOM of 0.4 and 0.65 was acquired before and after the density modification, respectively. Then the phase

information was used to build initial model with the program PHENIX.AutoBuild³⁶. The initial model was then completed through several cycles of manual model rebuilding in COOT³⁷ and refinement in Refmac5³⁸. The MHF-FANCM-F complex structure was further refined to 2.64 Å using PHENIX.refine³³ until all the density in the map could be interpreted well and all residues have acceptable chemical confirmation with 94% of the residues falling in most favored Ramachandran region and 6% in the allowed category.

The MHF complex structure was determined by molecular replacement using Molrep³⁹ in the CCP4i suite³⁵. The MHF dimer from the MHF-FANCM-F complex was used as the search model. The model from the Molrep was refined to the full resolution range against the native data of MHF using Refmac5³⁸, PHENIX.refine³⁶ and manual rebuilding in COOT³⁷. TLS restraint in the PHENIX.refine was used in the last several cycles of refinement. The final model gives 97% of residues residing in most favored region and 3% in allowed region. All structures were checked by MolProbity⁴⁰ and figures were prepared using PyMOL (DeLano Scientific LLC).

Electrophoretic Mobility Shift Assay

DNA-binding reactions (10 µl) were carried out for 1h at 4°C in binding buffer (20 mM Tris-HCl, pH7.5, 50 mM NaCl) with the indicated concentration of protein and 0.6 µM DNA. After the addition of 3 µl of gel loading buffer (50% glycerol, 0.02% bromophenol blue), the reaction mixtures were resolved in 5% native polyacrylamide gel in 0.5×TBE buffer (45 mM Tris-borate, 1 mM EDTA, pH 8.0) at 4°C for 60 min and visualized by Gel-Red-staining. The DNA probe is same to that used in fluorescence polarization assays.

Fluorescence Polarization Assays

Fluorescence polarization assays (FPAs) were performed at 298 K using a SpectraMax M5 microplate reader system in buffer containing 20 mM Tris-HCl pH 7.5, 50 mM NaCl. The wavelengths of fluorescence excitation and emission were 490 and 522 nm, respectively. Each well of a 384-well plate contained 100 nM fluorescent-labeled (5'-FAM) DNA probe and different amounts of protein complexes with a final volume of 80 µl. For each assay, DNA-free controls were included. The fluorescence polarization P (in mP units) was calculated with the equation: $P = (I_V - I_H) / (I_V + I_H)$. The fluorescence polarization change P (in mP units) was fit to the equation $P = P_{max} \times [protein] / (K_d + [protein])$ for one-site-bind mode and equation $P = P_{max}^1 \times [protein] / (K_d^1 + [protein]) + P_{max}^2 \times [protein] / (K_d^2 + [protein])$ for two-site-bind mode. The dsDNA probe used in the assays was formed by annealing ssDNA with complementary ssDNA. The sequence of ssDNA was: 5'-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCACCTGCAGGTT CACC-3'.

GST-pull-down assays

A similar amount of purified MHF complex was added to a similar amount of *E. coli* cells expressing recombinant GST-FANCM-F (GST-FANCM⁶⁶¹⁻⁸⁰⁰) or GST-FANCM⁶⁶¹⁻⁷³⁰, and then the mixtures were lysed in buffer containing 20 mM Tris-HCl pH 7.5, 200 mM NaCl. The supernatant was incubated with 100 µl of GST beads for 30 min at room temperature. Then the beads were washed two times with binding buffer. Finally, the bound

proteins eluted from the beads were resolved by SDS-PAGE (15%) and stained with Coomassie Brilliant Blue (BioRAD, USA).

Immunofluorescence microscopy

Aliquots of HeLa cells were transiently transfected to express MHF1, MHF2 and their mutants using lipofectamine 2000 as previously described⁴¹. Twenty-four hours after transfection, cells on glass coverslips were washed with warm PHEM (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl₂, pH 6.9) followed by 1 min of permeabilization with PHEM containing 0.1% Triton X-100 at 37°C followed by fixation in 3.7% paraformaldehyde for 5 min. After being washed three times with PBS, cells were blocked with 1% bovine serum albumin (BSA, Sigma) in PBS containing 0.5% Tween-20 for 30 min, then incubated with primary antibodies for 1 h, followed by secondary antibodies for 45 min. DNA was stained with 4',6-diamidino-2-phenylindole (DAPI, 1:10,000, Sigma) and human anti-centromere antibody (ACA; 1:500)⁴². Secondary antibodies were purchased from Invitrogen and used at a concentration of 1:400. Images were acquired every 0.25 μm at Z-axis to generate three-dimensional image stacks utilizing a Olympus 60×/1.42 Plan APO N objective on an Olympus IX71 microscope (Applied Precision DeltaVision personal). The three-dimensional image stacks were de-convolved, projected with SoftWorx (Applied Precision), and mounted in figures with Adobe Photoshop and Illustrator (Adobe)⁴³.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Don Hill for editorial assistance. This work is supported by grants from the Chinese 973 projects (2012CB917200, 2010CB912103, 2012CB945002, 2007CB914503 and 2002CB713700), Chinese Natural Science Foundation (31130018, 91129714, 90508002 and 91129714), Anhui Province Key Project Grant 08040102005, Chinese Academy of Science Grants KSCX1-YW-R-65, KSCX2-YW-H-10, and KSCX2-YW-R-195, International Collaboration Grant 2009DFA31010, Anhui Province Key Project Grant 08040102005, and National Institutes of Health (DK56292 and CA118948). X.Y. is a Georgia Cancer Coalition Eminent Scholar.

References

1. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. *Nat Rev Cancer*. 2003; 3:23–34. [PubMed: 12509764]
2. de Winter JP, Joenje H. The genetic and molecular basis of Fanconi anemia. *Mutation Res*. 2009; 668:11–19. [PubMed: 19061902]
3. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. *Nat Rev Genet*. 2007; 8:735–748. [PubMed: 17768402]
4. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. *Genes & development*. 2010; 24:1680–1694. [PubMed: 20713514]
5. Vaz F, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. *Nat Genet*. 2010; 42:406–409. [PubMed: 20400963]
6. Kim Y, et al. Mutations of the SLX4 gene in Fanconi anemia. *Nat Genet*. 2011; 43:142–146. [PubMed: 21240275]
7. Stoepker C, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. *Nat Genet*. 2011; 43:138–141. [PubMed: 21240277]

8. Garcia-Higuera I, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol Cell*. 2001; 7:249–262. [PubMed: 11239454]
9. Smogorzewska A, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. *Cell*. 2007; 129:289–301. [PubMed: 17412408]
10. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. *Mutation Res*. 2009; 668:54–72. [PubMed: 19622404]
11. Kratz K, et al. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. *Cell*. 2010; 142:77–88. [PubMed: 20603016]
12. Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. *Science*. 2010; 329:693–696. [PubMed: 20671156]
13. MacKay C, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. *Cell*. 2010; 142:65–76. [PubMed: 20603015]
14. Smogorzewska A, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. *Mol Cell*. 2010; 39:36–47. [PubMed: 20603073]
15. Meetei AR, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. *Nat Genet*. 2005; 37:958–963. [PubMed: 16116422]
16. Gari K, Decaillet C, Stasiak AZ, Stasiak A, Constantinou A. The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. *Mol Cell*. 2008; 29:141–148. [PubMed: 18206976]
17. Gari K, Decaillet C, Delannoy M, Wu L, Constantinou A. Remodeling of DNA replication structures by the branch point translocase FANCM. *Proc Natl Acad Sci U S A*. 2008; 105:16107–16112. [PubMed: 18843105]
18. Deans AJ, West SC. FANCM connects the genome instability disorders Bloom's Syndrome and Fanconi Anemia. *Mol Cell*. 2009; 36:943–953. [PubMed: 20064461]
19. Xue Y, Li Y, Guo R, Ling C, Wang W. FANCM of the Fanconi anemia core complex is required for both monoubiquitination and DNA repair. *Human Mol Genet*. 2008; 17:1641–1652. [PubMed: 18285517]
20. Singh TR, et al. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. *Mol Cell*. 2010; 37:879–886. [PubMed: 20347429]
21. Yan Z, et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. *Mol Cell*. 2010; 37:865–878. [PubMed: 20347428]
22. Foltz DR, et al. The human CENP-A centromeric nucleosome-associated complex. *Nat Cell Biol*. 2006; 8:458–469. [PubMed: 16622419]
23. Amano M, et al. The CENP-S complex is essential for the stable assembly of outer kinetochore structure. *J Cell Biol*. 2009; 186:173–182. [PubMed: 19620631]
24. Romier C, Cocchiarella F, Mantovani R, Moras D. The NF-YB/NF-YC structure gives insight into DNA binding and transcription regulation by CCAAT factor NF-Y. *J Biol Chem*. 2003; 278:1336–1345. [PubMed: 12401788]
25. Hartlepp KF, et al. The histone fold subunits of *Drosophila* CHRAC facilitate nucleosome sliding through dynamic DNA interactions. *Mol Cell Biol*. 2005; 25:9886–9896. [PubMed: 16260604]
26. Kamada K, et al. Crystal structure of negative cofactor 2 recognizing the TBP-DNA transcription complex. *Cell*. 2003; 106:71–81. [PubMed: 11461703]
27. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature*. 1997; 389:251–260. [PubMed: 9305837]
28. Sekulic N, Bassett EA, Rogers DJ, Black BE. The structure of (CENP-A-H4)₂ reveals physical features that mark centromeres. *Nature*. 2010; 467:347–351. [PubMed: 20739937]
29. Kim JM, Kee Y, Gurtan A, D'Andrea AD. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. *Blood*. 2008; 111:5215–5222. [PubMed: 18174376]
30. Zeitlin SG, et al. Double-strand DNA breaks recruit the centromeric histone CENP-A. *Proc Natl Acad Sci U S A*. 2009; 106:15762–15767.
31. Hua S, et al. CENP-U cooperates with Hec1 to orchestrate kinetochore-microtubule attachment. *J Biol Chem*. 2011; 286:1627–1638. [PubMed: 21056971]

32. Chu L, et al. SUV39H1 orchestrates temporal dynamics of centromeric methylation essential for faithful chromosome segregation in mitosis. *J Mol Cell Biol.* in the press.
33. Black BE, Cleveland DW. Epigenetic centromere propagation and the nature of CENP-a nucleosomes. *Cell.* 2011; 144:471–479. [PubMed: 21335232]
34. Minor W, O Z. Processing of X-ray diffraction data collected in oscillation mode. *Meth Enzymol.* 1997; 276:307–326.
35. Collaborative Computational Project, N. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D.* 1994; 50:760–763. [PubMed: 15299374]
36. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:213–221. [PubMed: 20124702]
37. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr.* 2004; 60:2126–2132. [PubMed: 15572765]
38. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr.* 1997; 53:240–255. [PubMed: 15299926]
39. Vagin A, T A. MOLREP: an automated program for molecular replacement. *J Appl Cryst.* 1997; 30:1022–1025.
40. Davis IW, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic acids Res.* 2007; 35:W375–383. [PubMed: 17452350]
41. Yao X, Abrieu A, Zheng Y, Sullivan KF, Cleveland DW. (2000) CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. *Nat Cell Biol.* 2000; 2:484–491. [PubMed: 10934468]
42. Chu Y, et al. Aurora B kinase activation requires survivin priming phosphorylation by PLK1. *J Mol Cell Biol.* 2011; 3:260–267. [PubMed: 21148584]
43. Huang Y, et al. CENP-E interacts with SKAP to orchestrate chromosome segregation in mitosis. *J Biol Chem.* 2012; 287:1500–1509. [PubMed: 22110139]




Figure 1. Overall structure of the MHF complex. **(a)** Ribbon representation of the MHF1-MHF2 heterodimer. MHF1 and MHF2 are colored in green and yellow, respectively, and the same color style is used in the all subsequent figures unless otherwise specified. Secondary structure element is termed based on that of Histones (see also **c** and **d**). **(b)** Ribbon diagram of the (MHF1-MHF2)₂ tetramer. The right one is an orthogonal view from the top of the left one. **(c)** Sequence alignment of human MHF1 with mouse, Xenopus, *S. cerevisiae*, and rice orthologs as well as H3 and NC2β. The identical and similar residues are depicted with red and magenta backgrounds, respectively. The residues designated with a green triangle are involved in the formation of (MHF1-MHF2)₂ tetramer. Residues labeled with a blue star reside in the MHF2 hydrophobic core. The residues in green backgrounds are located in the $\alpha1\alpha2$ site and those in green box are in the L1L2 site (see also **d**). **(d)** Sequence alignment of human MHF2. The inserted Proline in the $\alpha3$ is implicated with a green line. **(e)** MHF1-MHF2 dimer formation. Residues involved in the interactions are highlighted in green (MHF1) and yellow (MHF2) sticks. **(f)** Surface representation of (MHF1-MHF2)₂ tetramer colored by sequence conservation. The mostly conserved residues in MHF1 are colored in green and yellow for MHF2. Conserved residues form two clusters in three-dimensional space.




Figure 2. Structural comparisons of MHF with histone-fold proteins. **(a)** Comparisons of MHF with histones from nucleosome (PDB ID: 1AOI). H2A was in cyan, H2B in red, H3 in salmon and H4 in violet purple. The **(b)** closeup view highlights the Arg-Asp bidentate pair of MHF1. The **(c)** closeup view shows that MHF2 does not contain the bidentate pair. The **(d)** close-up view illustrates the difference of $\alpha 1$ helix in MHF1 and H2B. The **(e)** closeup view reveals the local environment causing the $\alpha 3$ kink of MHF2. **(f)** Overlay of $(\text{MHF1-MHF2})_2$ with $(\text{H3-H4})_2$. The dimer used for alignment is shown in a surface representation. The left close-up view highlights the $\alpha 2$ helix conformation and the bottom closeup view reveals the hydrophobic interactions. The trajectory of $\alpha 2$ helix was modeled with black dashes. **(g)** The specific interface of $(\text{MHF1-MHF2})_2$ tetramer. Residues participating in the interactions are shown in magenta sticks for one MHF1 molecule and cyan sticks for the pseudo-symmetry-related MHF1'.





Figure 3. FANCM-F binds to $(\text{MHF1-MHF2})_2$ tetramer. **(a)** Ribbon representation of the overall structure of MHF-FANCM-F complex, with FANCM-F in magenta. The dimer associating with the N-terminal part of FANCM-F is labeled as MHF and the other one interacting with the FANCM-F C-terminus is labeled as MHF'. **(b)** The extended structure of FANCM-F. **(c)** Representative experimental electron density map. Electron density map at 2.64 Å resolution contoured at 1.0 σ . The portion of FANCM-F residues 753-786 is shown. **(d)** The B-factor distribution of FANCM-F. The wider the tubing is, the higher the B-factor is. The missing residues 730-750 are modeled in magenta circles. **(e)** The N-terminal “V” segment wraps around the MHF1 $\alpha 1$ and $\alpha 2$ helices. Closeup view indicates the complementary hydrophobic interface between FANCM-F αA and MHF1 $\alpha 1$ helix. The involved residues are labeled in black, red and blue letters for FANCM-F, MHF1 and MHF2, respectively. **(f)** The C-terminal “V” segment surrounds the same region of MHF1' as in **e**. **(g)** The $\beta 2$ strand forms five hydrogen bonds with $\beta 1$. The black arcuate line indicates the trajectory of FANCM-F. **(h)** FANCM-F αB helix packs against $\alpha 3/\alpha 3'$ of MHF2/MHF1'. **(i)** The coil covers the surface area of partial $\alpha 2'$ and $\alpha 3'$ of MHF2'. Residues shown in sticks all make

contacts with MHF2. Val749 highlighted in cyan stick inserts its side chain into the MHF2 hydrophobic core. **(j)** The coil following $\beta 1$ extends to Gln714. FANCM-F Phe710 interacts with the MHF2 hydrophobic core with the aromatic ring. **(k)** The linker coil interacts with the bottom parts of MHF2 $\alpha 3$, viewed from the bottom in **i**. **(l)** Structure comparison of the two (MHF1-MHF2)₂ tetramers. MHF1 and MHF2 from the MHF complex are shown in orange and deep teal, respectively; those from the FANCM-F bound are shown green (MHF1) and yellow (MHF2), respectively. The line and the boxes indicate the region where difference occurs.

**Figure 4.**

Formation of the (MHF1-MHF2)₂ tetramer is essential for MHF function in vivo. (a) Dimeric complex of MHF1 is disrupted by His71A and Asp81A mutations. Immunoprecipitation results show that wild type Flag-MHF1 pulls down GFP-MHF1 (lane 3) but not MHF1^{H71A/D81A} mutant (lane 4). (b) (MHF1-MHF2)₂ tetramer is essential for a stable localization to centromere. GFP-MHF1 is readily apparent as it colocalizes with centromere mark ACA (anti-centromere autoantibody; upper panel merge). GFP-MHF1^{H71A/D81A} failed to localize to the centromere as the GFP signal was not concentrated to the centromere (lower panel). (c) Integral (MHF1-MHF2)₂ is essential for a stable localization to centromere. GFP-MHF2 is readily apparent as it colocalizes with centromere mark ACA (upper panel merge). GFP-MHF2^{D80A/F81A} failed to localize to the centromere as the GFP signal was not concentrated to the centromere (lower panel). (d) MHF1-MHF2 heterodimer is perturbed by mutation of MHF2^{D80A/F81A}. Western blot analysis results show that MHF1 pulls down GFP-MHF2 (lane 3) but not MHF2^{D80A/F81A} mutant (lane 4).




Figure 5.

The MHF complex has DNA-binding activity. Calculated electrostatic on the surface of (MHF1-MHF2)₂ tetramer (a) and (H3-H4)₂ from nucleosome (PDB ID: 1AOI) (b). Red and blue surfaces represent negative and positive electrostatic potentials ($-3.5 k_B T$, $+3.5 k_B T$), respectively. The electrostatic potentials were calculated using the Adaptive Poisson-Boltzmann Solver (APBS) with PyMol APBS tools. (c) Model of (MHF1-MHF2)₂ bound to DNA. Nucleosomal DNA was docked onto (MHF1-MHF2)₂ tetramer through alignment of MHF1-MHF2 dimer with H2A-H2B (PDB ID: 1AOI). The left blue circle indicates the $\alpha 1\alpha 2$ site, the middle one for L1L2 site and the right one for MHF1 C-terminus. (d) L1L2 site and αC helix would face the bound DNA modeled by alignment of MHF1 with NC2 β (blue). (e) EMSA results of MHF1-MHF2 complex and the mutants. 0.6 μM DNA substrate (59bp, **Methods**); proteins at lanes 1-3 (MHF1^{R12A/R18A}/MHF2^{R11A/K12A}): 0, 5, 10 μM , respectively; lanes 4-6 (MHF1/MHF2^{K27A/K29A}): 5, 10, 20 μM , respectively; lanes 7-8 (MHF1^{K73A/R74A}/MHF2): 10, 20 μM , respectively; lanes 9-10 (MHF1/MHF2): 5, 10 μM , respectively. (f) FPAs of MHF1/MHF2 and MHF1/MHF2^{K27A/K29A}. The data of wild type MHF was fitted according to Equation 2 (**Methods**). (g) FPAs of mutant MHF complexes, MHF1/MHF2^{K27A/K29A} and MHF1^{R110A/K111A}/MHF2. (h) The DNA-binding effect of C-

terminus deletion on MHF1. 0.6 μ M DNA substrate; proteins at lanes (MHF1/MHF2) 1-3: 0, 5, 10 μ M; lanes 4-5 (MHF1¹⁻¹⁰⁷/MHF2): 20 μ M, 50 μ M; lanes 6-8 (MHF1¹⁻¹¹⁴/MHF2): 5, 20, 50 μ M, respectively.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. MHF-FANCM-F complex possesses two DNA-binding sites. **(a)** Calculated electrostatic on the surface of $(\text{MHF1-MHF2})_2$ bound to FANCM-F. Though some of the labeled residues shown in spheres (right one) having missing atoms in the final model, intact residues rebuilt in COOT were used for surface potential calculation. As a control, the surface potential of $(\text{MHF1-MHF2})_2$ alone are shown in **(b)**. Red and blue surfaces represent negative and positive electrostatic potentials ($-3.5 \text{ k}_B\text{T}$, $+3.5 \text{ k}_B\text{T}$). **(c)** FPA of MHF1/MHF2/FANCM-F. The data was fitted according to Equation 3 (**Methods**). Blue dashes represent the results of data fitting according to Equation 2. Clearly, it is largely divergent from the experimental data. **(d)** EMSA results of the FANCM-F in complex with MHF mutants. $0.6 \mu\text{M}$ DNA substrate; proteins at lanes 1-4 (MHF1^{K73A/R74A}/MHF2/FANCM-F): 0, 5, 10, 20 μM , respectively; lanes 5-6 (MHF1/MHF2^{K27A/K29A}/FANCM-F): 5, 20 μM , respectively; lane 7 (MHF1^{K73A/R74A}/MHF2): 20 μM ; lane 8 (MHF1/MHF2^{K27A/K29A}): 20 μM . **(e)** EMSA results of the FANCM-F mutants in complex with MHF mutants. $0.6 \mu\text{M}$ DNA substrate; proteins at lanes 1-3 (MHF1^{R12A/R18A/K73A/R74A}/MHF2/FANCM-F^{K686A/R690A/R693A}): 0,

5, 20 μ M, respectively; lanes 4-5 (MHF1^{K73A/R74A}/MHF2/FANCM-F^{K686A/R690A/R693A}): 5, 20 μ M, respectively; lane 6-7 (MHF1^{K73A/R74A}/MHF2^{R11A/K12A}/FANCM-F^{K675A/K676A}), 5, 20 μ M; lane 8-9 (MHF1^{K73A/R74A}/MHF2/FANCM-F^{K675A/K676A}): 5, 20 μ M, respectively; lane 10 (MHF1^{K73A/R74A}/MHF2/FANCM-F): 20 μ M. **(f)** MHF1¹⁻¹¹⁴/MHF2/FANCM-F still binds to DNA. But the data could only be fitted in one-site-binding mode. **(g)** The DNA-binding trajectory in the MHF-FANCM-F complex. MHF1 C-terminus locates in the junction of the two DNA-binding paths shown orange strip and the MHF1 C-terminal residues may follow a trajectory similar to that of α 4 helix of NC2 β shown in blue.




Figure 7. MHF-FANCM physical contact is essential for a stable localization of FANCM to chromatin. **(a)** MHF1 is essential for a stable localization of FANCM to centromere. GFP-FANCM is readily apparent at the centromere in the scramble siRNA-treated cells (upper panel merge). GFP-FANCM failed to localize to the centromere in the absence of MHF1 (lower panel). **(b)** (MHF1-MHF2)₂ tetramer is essential for a stable FANCM association with chromatin. **(c)** Schematic diagram of structure perturbation in disease-associated mutant FANCM^{S724X}. **(d)** Stable MHF-FANCM-F association requires a physical contact between MHF and FANCM-F. GST pull-down results show that MHF binds to FANCM-F (FANCM⁶⁶¹⁻⁸⁰⁰) (lane 1), but not FANCM⁶⁶¹⁻⁷³⁰ (lane 2). **(e)** Perturbation of MHF-FANCM association abrogates the localization of FANCM to chromatin. GFP-FANCM is readily apparent at the centromere as it colocalizes with ACA and MHF1 (upper panel). GFP-FANCM¹⁻⁷²³ failed to localize to the centromere (lower panel).

Table 1
Data collection and refinement statistics

Data Collection		
	MHF1¹⁻¹⁰⁷-MHF2	MHF1¹⁻¹¹⁴-MHF2-FANCM-F
	Native	SeMet
Space group	<i>P2</i> ₁	<i>P2</i> ₁
Cell dimensions (Å)		
a, b, c (Å) α, β, γ (°)	41.01, 128.77, 88.70 90.00, 100.74, 90.00	111.32, 70.03, 115.75 90.00, 91.41, 90.00
Wavelength (Å)	0.9794	0.9792
Resolution (Å) ^a	50.00-2.41 (2.45-2.41)	50-2.64 (2.73-2.64)
Total reflections	125710	351195
Unique reflections	32631 (1477)	52925 (5221)
Redundancy	3.9 (3.1)	6.6 (6.2)
R _{merge} (%) ^b	7.3 (47.2)	10.6 (45.9)
I/σ (I)	16.03 (2.53)	24.31 (4.62)
Completeness (%)	94.1 (86.4)	100 (100)
Refinement		
Resolution	34.15-2.41 (2.50-2.41)	49.67-2.64 (2.73-2.64)
Unique reflections	31356 (2407)	50516 (4254)
R _{work} (%) ^c	19.04 (23.72)	22.05 (27.91)
R _{free} (%) ^c	24.17 (30.98)	25.56 (33.12)
Number of atoms		
Residue	677	1344
Protein	5271	10388
Water	116	120
B factors (Å ²)		
Protein	44.73	45.04
Water	43.94	41.50
Rmsd		
Bond lengths (Å)	0.003	0.002
Bond angles (°)	0.557	0.539

^aHigh-resolution shell is shown in parentheses.

^bR_{merge} = $\sum |I_i - \langle I \rangle| / \sum I_i$, where I_i is the intensity of an individual reflection and $\langle I \rangle$ is the average intensity of that reflection.

^cR_{work} = $\sum ||F_o| - |F_c|| / \sum |F_o|$ for all reflections and R_{free} = $\sum ||F_o| - |F_c|| / \sum |F_o|$, calculated on the 5% of data excluded from refinement.